

PRE-APPEAL BRIEF REQUEST FOR REVIEW

Docket Number (Optional)

207,380

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)]

on _____

Signature _____

Typed or printed name _____

Application Number

10/561,670

Filed

December 19, 2005

First Named Inventor

Franco Macchi

Art Unit

1623

Examiner

BLAND, Layla D.

Applicant requests review of the final rejection in the above-identified application. No amendments are being filed with this request.

This request is being filed with a notice of appeal.

The review is requested for the reason(s) stated on the attached sheet(s).

Note: No more than five (5) pages may be provided.

I am the

☐ applicant/inventor.

/Jay S. Cinamon/

☐ assignee of record of the entire interest.

See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed.
(Form PTO/SB/96)

Jay S. Cinamon

Signature

Typed or printed name

☒ attorney or agent of record.

Registration number 24,156

212-885-9232

Telephone number

☐ attorney or agent acting under 37 CFR 1.34.

Registration number if acting under 37 CFR 1.34 _____

June 1, 2011

Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.

Submit multiple forms if more than one signature is required, see below.

☒ *Total of 3 forms are submitted.

This collection of information is required by 35 U.S.C. 132. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11, 1.14 and 41.6. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Macchi	Confirmation No.:	5848
Serial No.:	10/561,670	Art Unit:	1623
Filed:	December 19, 2005	Examiner:	BLAND, Layla D.
		Attorney Docket No.:	207,380
Title:	USE OF HYALURONIC ACID FOR PREPARING COMPOSITIONS FOR TREATING ORAL CAVITY APHTHAS		

PRE-APPEAL BRIEF REQUEST FOR REVIEW

TO THE COMMISSIONER FOR PATENTS:

Applicant requests review of the final rejection in the above-identified application. No amendments are being filed with his request. This request is being filed with a Notice of Appeal.

The review is requested for the reason(s) stated below, and no more than five (5) pages have been provided.

Claims 7-13 are pending and stand rejected. Briefly, Claim 7 is directed to a method for the treatment of Recurrent Oral Aphthous Ulcers (ROAU) comprising administering, as the sole active ingredient, hyaluronic acid or a salt thereof, having an average molecular weight comprised between 800,000 and 4,000,000, to a subject in need thereof. Claims 8, 12 and 13 depend from Claim 7, Claim 9 depends from Claim 8, Claim 10 depends from Claim 9, and Claim 11 depends from Claim 10.

Claims 7-13 are rejected under 35 U.S.C. § 103(a) as obvious over Di Schiena (European Patent No. EP 0444492) in view of Saxen (Saxen et al., Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:356-61).

1. Di Schiena in view of Saxen, Fails to Teach or Suggest Every Limitation of the Claimed Invention

- (i) **Saxen fails to teach or suggest that hyaluronic acid (HA), as the sole active ingredient, is useful for therapy of RAS.**

The Examiner improperly supports the obviousness rejection over Di Schiena in view of Saxen and fails to show that the claimed invention is taught or suggested by the art.

The Examiner states that *Di Schiena teaches pharmaceutical compositions comprising 0.2 to 10% sodium hyaluronate having molecular weight between 800,000-4,000,000, preferably 1,000,000-2,000,000 for the treatment and prophylaxis of inflammatory affections of the oral cavity.*

The Examiner also affirms that *Di Schiena does not exemplify the treatment of recurrent oral aphthous ulcers using the composition.*

In the Office Action of February 3, 2011 ("O.A.6"), page 3, par.1, the Examiner affirms (and already indicated in the Office Action of March 9, 2009 ("O.A.3") page 6, par.3) that: *Saxen teaches that recurrent aphthous ulcers are a common disorder, causing pain from inflammatory sensitization of nerve endings.... Adults having aphthous ulcers were treated with 3% diclofenac in 2.5% hyaluronan, 2.5% hyaluronan or 3% viscous lidocaine. A 48% reduction in pain was observed 10 minutes after application with no significant difference between the three topical agents [see abstract].*

The distinguishing features of the method as recited in present Claim 7 are:

- the pathology to be treated: recurrent oral aphthous ulcers (ROAU);
- **the sole active ingredient: hyaluronic acid;**
- the average molecular weight of the hyaluronic acid: comprised between 800,000 and 4,000,000.

In contrast to these distinguishing features, Saxen teaches that **hyaluronan (HA) alone is not effective** on ROAU. In fact in Applicant's response of September 26, 2008 ("Resp.2") page 5, last par., Applicant points out that the Examiner's affirmations are incorrect since she relies on the abstract of Saxen on which to base her reasoning.

Applicant reiterated this in the Response of July1, 2009 ("Resp3") page 6, in the Response of April 20, 2010 ("Resp.4") pages 4-5, and also in the Response of January 4, 2011 ("Resp.5") page 2, last two paragraphs.

Applicant pointed out that this basis is not correct because the data for the reduction of 48% in pain refers only to the preparation of diclofenac/HA as clearly stated at page 359, 1st column, lines 5-9, wherein it is stated that for diclofenac/HA a highly significant effect was observed and *"neither lidocaine nor hyaluronan were significantly different from baseline pain level"*.

Therefore, the abstract of Saxen, if read correctly and in its entirety, does not teach that HA would be useful for the treatment of recurrent oral aphthous ulcers, but that **diclofenac/HA gel** can be used in the treatment.

To the extent the Examiner mistakenly relies upon this section of Saxen to support the obviousness rejection, the rejection is improper.

Applicant furthermore underscores the fact that there is no teaching in Saxen that HA is effective for the treatment of ROAU and that, on the contrary, as explained in Resp.5, page 2, par.4, Saxen reports that *“A 35% to 52% pain reduction ($p < 0.01$) was reported 2 to 6 hours after the application of diclofenac in hyaluronan, while hyaluronan gel alone and viscous lidocaine failed to produce significant VAS reduction”* (emphasis added).

Failing to consider references as a whole in making an obviousness rejection is an error on the part of the Examiner (M.P.E.P. §2141.02) and, therefore, the rejection cannot stand.

Saxen fails to teach that HA alone is effective in the treatment of ROAU, a pathology of unknown origin and which is very difficult to treat, and the obviousness rejection is therefore improper to the extent that the Examiner relies upon the abstract of Saxen to support the obviousness rejection.

(ii) Saxen fails to teach or suggest that hyaluronic acid (HA) is an active principle.

In O.A.6, page 4, last 3 lines of par.2, the Examiner affirms that *based on Saxen's teaching alone, the skilled artisan would conclude that HA alone is effective for short-term pain relief due to oral aphthous ulcers.*

In the Office Action of July 7, 2010 (“O.A.5”), page 5, last 2 lines of par.3, the Examiner states that *even if Saxen is interpreted to suggest only immediate pain relief, pain management is the common treatment for ROAU, as taught by Saxen.* Applicant contests this affirmation, which is the Examiners’ deduction since Saxen states at page 360, 1st column, beginning of par..3 *“the blunting action of hyaluronan, an agent with no known analgesic or anaesthetic activity....”* (emphasis added) and after a comparison with carboxymethylcellulose in the following paragraph states that HA is *“a similar, pharmacologically inert agent”* (emphasis added).

How could HA be used for the treatment of a pathology if the teaching of Saxen is that HA is a pharmacologically inert agent? Saxen fails to teach that *“HA alone can be used to treat recurrent aphthous ulcers”* (O.A.6, page 3, lines 5-6 of Par.2). This rejection is improper since a *pharmacologically inert agent* is not equivalent to an agent which is used to treat a pathology. This interpretation is corroborated throughout Saxen, for example at page 356, 2nd column, last two lines *“ability of the hyaluronan vehicle to transport diclofenac”* (emphasis added).

Saxen therefore fails to teach that HA alone can be used to treat ROAU, and the obviousness rejection is improper in view of the Examiner's misinterpretation of the teaching of Saxen.

(iii) Saxen fails to teach or suggest that hyaluronic acid (HA) is effective in the reduction of lesion size.

In the Office Action of October 21, 2009 ("O.A.4), page 5, last paragraph, the Examiner affirms that *"Table 1 clearly teaches that there was a reduction in lesion size. The maximum lesion size went from 9 to 6, a 30% reduction, and the smallest ulcer size went from 3 to 0."*

Applicant explained in Resp.4, page 5 and reiterated this argument in Resp.5, page 3, par. 5, that: Table 1 of Saxen, indicates demographic characteristics of the treatment groups, that Table 1 clearly indicates p value of the lesion size, which are not significant, and most importantly that this is **confirmed by Saxen himself**, who stated *"No significant change in ulcer diameter or clinical appearance of the ulcer was observed throughout of the trial."* Page 358, 2nd column, lines 9-11 of last paragraph.

Since Saxen fails to teach that HA is effective in the reduction of lesion size, the skilled person having read Saxen would, without doubt, be led to *disregard its teachings* and would not be encouraged to use HA for reducing mouth lesions with a reasonable expectation of achieving the desired result. To the extent the Examiner erroneously reads the explicit teachings of the prior art, relies upon Table 1 to support the obviousness rejection, and asserts that this reference reads on the present claims, the rejection is improper.

Since the teachings of Saxen fail to cure the deficiencies of Di Schiena teachings for achieving the objectives of the claimed invention, the obviousness rejection is unsupported.

Conclusion

In view of the foregoing remarks, and as supplemented by Applicant's responses of record, the pending claims clearly distinguish over the combined teachings of Di Schiena in view of Saxen.

Withdrawal of the obviousness rejection is, therefore, respectfully solicited.


Please charge any fees which may be due and which have not been submitted herewith to our Deposit Account No. 01-0035.

Respectfully submitted,

ABELMAN, FRAYNE & SCHWAB
Attorneys for Applicant

Date June 1, 2011

By


Jay S. Cinnamon
Attorney for Applicant
Reg. No. 24,156

666 Third Avenue
New York, NY 10017-5621
Tel.: (212) 949-9022
Fax: (212) 949-9190